Brief: Medicenna Strengthens Ip Portfolio With U.S. Patent Granted For The Use Of Interleukin-2 Superkine Fusion Proteins In Oncology
01/08/2023 14:35
Aug 1 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA STRENGTHENS IP PORTFOLIO WITH U.S. PATENT
GRANTED FOR
THE USE OF INTERLEUKIN-2 SUPERKINE FUSION PROTEINS IN ONCOLOGY
Source text for Eikon: ID:nGNX5mkLWV
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results